Abstract 101P
Background
Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Despite the availability of multiple treatment strategies, the prognosis of the patients with CRC is dismal. The aim of this study is to evaluate the efficacy and safety of cellular immunotherapy (CIT) (the use of autologous natural killer cells, γδTcells and cytokine-induced killer cells) in combination with chemotherapy in patients with CRC.
Methods
A retrospective analysis of 377 patients with colorectal adenocarcinoma from December 2010 to December 2015 was performed, including 97 patients in the CIT+chemotherapy group and 280 patients in the chemotherapy group. The primary endpoints were DFS or PFS (Patients with adjuvant therapy after radical resection of colorectal cancer had the same DFS as PFS). The secondary endpoints were OS, ORR, DCR, adverse reaction rate and treatment tolerance.
Results
The 3-year progression-free survival rate of CIT+chemotherapy group and chemotherapy group was 67.2% vs 53.9% (P < 0.01), and the 5-year OS rate was 74.1% vs 50.8% (P < 0.001). CIT+chemotherapy was independent prognostic factors for both DFS (HR: 0.618, 95% CI: 0.428–0.891) and OS (HR: 0.513, 95% CI: 0.335–0.784). The ORR and DCR of CRC patients with IV staging in the CIT+chemotherapy compared to chemotherapy group were 63.0% vs 50.8% (P = 0.291) and 81.5% vs 65.6% (P = 0.131) respectively. The percentage of CD3+, CD3+ CD4+ cell subsets were significantly increased from 70.11% to 75.87% (P < 0.01), and 42.53% to 44.39% (P = 0.02) in the CIT+chemotherapy group after treatment. Overall adverse reaction rate of CIT+chemotherapy group and chemotherapy group was 75.3% vs 75.4% (P = 0.98) respectively. In patients with stage III, the median chemotherapy course in CIT +chemotherapy compared to chemotherapy group is 8 vs 6 (P = 0.003).
Conclusions
High quality and standardized CIT combined with chemotherapy can promote the survival time, reduce the recurrence rate and improve the immune status of CRC patients. In addition, it is safe and low-toxic which improves the patient's tolerance to chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract